Review Article



MiR-29a: a potential therapeutic target and promising biomarker in tumors

Jin-yan Wang^{1,*}, Qian Zhang^{1,*}, Dan-dan Wang¹, Wei Yan¹, Huan-huan Sha², Jian-hua Zhao³, Su-jin Yang¹, He-da Zhang⁴, Jun-chen Hou¹, Han-zi Xu⁵, Yun-jie He¹, Jia-hua Hu², Shan-liang Zhong³ and Jin-hai Tang⁶

¹Department of General Surgery, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing 210009, P.R. China; ²The Fourth Clinical School, Nanjing Medical University, Nanjing 210029, P.R. China; ³Center of Clinical Laboratory Science, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Hospital of Nanjing Medical University, Nanjing 210009, P.R. China; ⁴Department of General Surgery, Southeast University Medical School, Nanjing, Jiangsu, P.R. China; ⁵Department of Radiation Oncology, Jiangsu Cancer Hospital , Nanjing, Jiangsu, P.R. China; ⁶Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, P.R. China

Correspondence: Shan-liang Zhong (slzhong@foxmail.com) or Jin-hai Tang (tangjh@njmu.edu.cn)



MiRNAs, small non-coding RNA molecules, were recognized to be associated with the incidence and development of diverse neoplasms. MiRNAs were small non-coding RNAs that could regulate post-transcriptional level by binding to 3'-UTR of target mRNAs. Amongst which, *miR-29a* was demonstrated that it had significant impact on oncogenicity in various neoplasms through binding to critical genes which enhanced or inhibited the progression of cancers. *MiR-29a* participated in kinds of physiological and pathological processes, including virus replication, cell proliferation, differentiation, apoptosis, fibrosis, angiogenesis, tumorigenicity, metastasis, drug-resistance, and so on. According to its sufficient sensitivity and specificity, many studies showed that *miR-29a* might serve as a potential therapeutic target and promising biomarker in various tumors. In this review, we discussed the functions of *miR-29a* and its potential application in the diagnosis, treatment and stages of carcinoma, which could provide additional insight to develop a novel therapeutic strategy.

Introduction

Mortality caused by cancer is soaring globally, which urgently requests us to figure out a safe and effective way to further improve overall survival of tumor patients [1]. Then, molecular targetting treatment of cancer entered our sight and brought cancer patients a ray of dawn. Based on massive researches, 🛓 miRNAs appeared to modulate various pathways in malignant neoplasms, which might offer a brand g new and effective way in future molecular targetting cancer treatment [2,3]. MiRNAs are a class of small, highly conserved, time sequencing, and non-coding RNAs, including 18-25 nts, that regulate gene expression at both transcriptional and post-transcriptional levels. They are involved in different biological and metabolic processes, through binding to the 3'-UTRs of mRNAs [4]. Additionally, miRNAs are disclosed that they are related to many biological processes including cell proliferation, apoptosis, angiogenesis, drug-resistance, invasion, and metastasis [5]. Cho [6] had summarized miRNAs as a potential biomarker for diagnosis, prognosis, and therapy with ample evidence in cancers. Liu et al. [7] highlighted multifarious miRNAs participated in the regulation of chemoresistance, cell cycle, and apoptosis in the process of epithelial-to-mesenchymal transition (EMT), cell cycle, and apoptosis in colorectal cancer (CRC) cells. For instance, miR-139-5p inhibited cell proliferation of breast cancer (BCa) [8]. MiR-335 promoted gastric cancer (GC) cell apoptosis by targetting CT10 oncogene homolog-like (CRKL) [9]. MiR-222 mediated adriamycin resistance to BCa cells [10]. MiR-22 decreased migration due to down-regulating CD147 expression in tongue squamous cell carcinoma (TSCC) [11].

gst ous ion insis, *v*ity utic ons ma, d efrreatches Downloaded from http://port.silverchair.com/bioscirep/article-pdf/38/1/BSR20171265/429626/bsr-2017-1265.pdf by guest on 19

*These authors contributed equally to this work.

Received: 15 September 2017 Revised: 05 December 2017 Accepted: 06 December 2017

Accepted Manuscript Online: 06 December 2017 Version of Record published: 08 February 2018



MiR-29 family (miR-29a, miR-29b, and miR-29c) was connected with aggressiveness and prognosis of malignant neoplasms and might act as a considerable biomarker for forecasting the recurrence and progression of cancers [12-15]. Nonetheless, from articles we have learnt that *miR-29a* and *miR-29b* appeared to be more effective than *miR-29c* in targetting genes and signaling pathways [16,17]. The role of *miR-29b* in cancers had been fully discussed by Yan et al. [18] in 2015 and the new progression of miR-29b was less. Yet, the function of miR-29a had not been sufficiently summarized. On account of available researches, miR-29a had been found to be associated with kinds of neoplasms. For instance, it was down-regulated in metastatic prostate cancer (PCa) [19], myeloid leukemias [20], endocrine-sensitive BCa [21], lung cancer [22], ALK-positive anaplastic large cell lymphomas (ALCLs) [23], oral squamous carcinoma (OSCC) [24], glioblastoma [25]. Interestingly, other findings proclaimed that miR-29a was up-regulated in cholangiocarcinoma [26], CRC [27], and so on. Apart from its role in cancer, miRNAs were also involved in a variety of non-malignant diseases. According to Wei et al. [28], miRNAs served as a potential biological role in the initiation of pulmonary inflammation. Without exception, miR-29a was correlated with kinds of non-malignant diseases, like Alzheimer's disease [29], cholestatic pediatric liver disease [30], atherosclerosis [31], atrial fibrillation [32], active pulmonary tuberculosis [33], thoracic aneurysms [34], tendon disease [35], hepatic fibrosis [36], ankylosing spondylitis [37], diabetes [38], scleroderma [39], and fatty liver disease [40]. Besides, evidence had proved that miR-29a greatly participated in multifarious cell processes, such as cell proliferation, apoptosis, angiogenesis, invasion, and metastasis and drug-resistance [41-43]. Thus it could been seen that miR-29a might play a considerable role in the adjustment of kinds of diseases, especially cancers. In this review, we will focus on the action of miR-29a in the processes of cell proliferation, apoptosis, angiogenesis, invasion, metastasis, and drug resistance, and work out the network of genes modulating its functions, and predict the potential role of miR-29a in the diagnosis and molecular targetted therapy of human cancers.

MiR-29a in cell proliferation

An increasing number of studies showed that *miR-29a* was correlated with proliferation to a great extent. TUT1, a nucleotidyl transferase, could increase the expression of miR-29a, then inhibiting PPARy and SREBP-1c expression, which suppressed cell proliferation in osteosarcoma (OS) [44]. Li et al. [41] discovered that miR-29a repressed PCa cell proliferation and development of PCa through targetting lysine demethylation 5B (KDM5B). KDM5B could specifically reduce the methylation levels of histone H3 at lysine 4 (H3K4). Additionally, Cui et al. [45] confirmed that, in GC, miR-29a could suppress the expression level of p42.3 which had been proved to be associated with cell proliferation. Consequently, miR-29a might act as an inhibitor in the modulation of cell proliferation. Lately, Zhao et al. [46] also found that, in vitro, enhancing the expression of miR-29a could decrease cell proliferation in GC via diluting the level of Cyclin-dependent kinase (CDK) 2 (CDK2), CDK4, and CDK6. Furthermore, cell proliferation could also be directly refrained by miR-29a through suppressing the expression of Mucin 1 (MUC1). MUC1 was a membrane-bound glycoprotein, interacting with the epidermal growth factor receptor (EGFR) [47]. Besides, MUC1, targetted by miR-29a, was also lately confirmed to accommodate in pancreatic ductal adenocarcinoma (PDAC) cell proliferation through p42-44 MAPK and β-catenin pathways [48]. Moreover, according to Xi et al. [25], miR-29a repressed the level of Wilms' tumor 1-associating protein (WTAP), phosphoinositide 3-kinase (PI3K)/protein kinase B (PKB)/AKT and extracellular signal-related kinase pathways through targetting Quaking gene isoform 6 (QKI-6) in glioblastoma stem cells (GSCs), accordingly inhibiting cell proliferation. Zhu et al. [49] recognized that osteonectin (SPARC) restrain the phosphorylation of AKT/mTOR, via the overexpression of miR-29a, thus controlling cancer cell proliferation in hepatocellular carcinoma (HCC). MiR-29a was claimed to have the ability to decreased proliferation in non-small-cell lung cancer (NSCLC), via negatively correlating with LIM and SH3 domain protein 1 (LASP1), a cAMP- and cGMP-dependent signaling protein and a member of the nebulin family of actin-binding proteins [50]. At the same time, the suppression of proliferation caused by miR-29a was also affirmed by Li et al. [51] partly via targetting cell division control protein 42 homolog (CDC42) in NSCLC. In addition, Pei et al. [52] demonstrated that, in BCa cells, miR-29a could induce cell proliferation by directly targetting ten eleven translocation (TET) 1 (TET1). TET1 was a member of the TET family and able to alter 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), which could induce CpG island demethylation in specific gene promoter [53]. Nonetheless, the newest research acknowledged miR-29a remarkably weakened cell proliferation in MCF-7 cells, one BCa cells, partly through tumor necrosis factor (TNF) receptor (TNFR) associated factor 1 (TNFR1), the prime receptor that commanded TNF- α -induced cellular events [54]. The absolutely opposite standpoint might be worthy of further discoveryFigures 1-5 and Tables 1-3



Table 1 Target genes and dysregulation of miR-29a in proliferation, apoptosis, angiogenesis, and drug resistance

hsa- <i>miR-29a</i>	Diseases	Target genes	References	Participation	
Down-regulated	PCa	KDM5B	Li et al. [41]	Proliferation	
				Apoptosis	
	GC	p42.3	Cui et al. [45]	Proliferation	
		CDK2	Zhao et al. [46]	Proliferation	
		CDK4			
		CDK6			
		VEGF	Zhang et al. [42]	Angiogenesis	
	PDAC	MUC1	Trehoux et al. [47,48]	Proliferation	
				Drug resistance	
	Pancreatic cancer	Wnt/β-catenin	Cai et al. [65]	Drug resistance	
	GSCs	QKI-6	Xi et al. [25]	Proliferation	
				Apoptosis	
	HCC	SPARC	Zhu et al. [49]	Proliferation	
	NSCLC	LASP1	Hu et al. [50]	Proliferation	
		CDC42	Li et al. [51]	Proliferation	
	(ALK+)ALCL	MCL-1	Desjobert et al. [23]	Apoptosis	
	BCa	TNFR1 Zhao et al. [54] Proliferation	Proliferation		
				Apoptosis	
	OSCC	MMP2	Lu et al. [24]	Apoptosis	
	Glioma	VASH2	Jia et al. [58]	Angiogenesis	
	OS	TUT1	Zhu et al. [44]	Proliferation	
Up-regulated	BCa	TET1	Pei et al. [52]	Proliferation	
		HSPs	Choghaei et al. [56]	Apoptosis	

Abbreviations: ALCL, anaplastic large cell lymphoma; HSP, heat shock protein; MCL-1, myeloid cell leukemia 1; MMP2, matrix metalloproteinase 2; VASH2, vasohibin 2; VEGF, vascular endothelial growth factor.




Figure 1. *MiR-29a* targetted p42.3, CDK2, CDK4, CDK6, MUC1, QKI-6, SPARC, CDC42, TNFR1 and thus inhibited proliferation

However, *miR-29a* could also induce proliferation though KDM5B, TET1, PPARγ, SREBP-1c, LASP1.






Figure 2. MCL-1, KDM5B, QKI-6, MMP2, TNFR1 are the five target genes of *miR-29a* and *miR-29a* inhibited their functions and promoted apoptosis

On the other hand, *miR-29a* decreased apoptosis by refraining HSP60 and motivating HSP27, HSP40, HSP70, HSP90. Abbreviations: HSP, heat shock protein; MCL-1, myeloid cell leukemia 1; MMP2, matrix metalloproteinase 2.




Figure 3. VASH2 and VEGF, inhibited by *miR-29a*, acted in a stimulative role in angiogenesis

But, HBP1 and PTEN, which were also restrained by *miR-29a*, lessened angiogenesis. Abbreviations: HBP1, HMG box-containing protein-1; PTEN, phosphatase and tensin homolog; VASH2, vasohibin 2; VEGF, vascular endothelial growth factor.




Figure 4. *MiR-29a* magnified drug resistance via targetting PREN/AKT/GSK3 β and Wnt/ β -catenin and reduced drug resistance by binding to MUC1

MiR-29a in cell apoptosis

Apoptosis was recognized as a highly regulated and controlled process of cell death that occurred in multicellular organisms. It was activated through two pathways, including the intrinsic pathway and the extrinsic pathway, both of which induced cell death by activating caspases, such as proteases or enzymes that degraded proteins [55]. An increasing number of researches had demonstrated that *miR-29a* played a significant role in promoting apoptosis via targetting several relevant effectors in human cancer. Desjobert et al. [23] claimed that the expression of *miR-29a* was






Figure 5. Up-regulated *miR-29a* targetted TET1, MCL-1, LASP1, ITGB1, TFEB, ATG9A, Robo1, PI3K/AKT, MMP2, CEACAM6, TRIM68, PGK-1, TRAF4, VEGF-A, LOXL2, CDC42 directly and inhibited the expression of them resulting in decreasing cell metastasis

Additionally, *miR-29a* could enhance metastasis via HUR, PTEN, TTP, KLF4. Abbreviations: CEACAM6, carcinoembryonic antigen-related cell adhesion molecule 6; ITGB1, integrin β1; MCL-1, myeloid cell leukemia 1; MMP2, matrix metalloproteinase 2; PTEN, phosphatase and tensin homolog; Robo1, roundabout 1; TTP, tristetraprolin; VEGF, vascular endothelial growth factor.

critically decreased by an active NPM-ALK kinase in ALK-positive (ALK+) ALCL cells, partly through methylation regulation. And this kind of modulation played a fundamental role in the high expression of myeloid cell leukemia 1 (MCL-1). MCL-1, a major anti-apoptotic BCL-2 family member localized to the mitochondrial membrane of ALK+ ALCL cell, acted as a promotor in tumor cell survival through suppressing apoptosis. Moreover, *miR-29a* in PCa cell lines (PC-3 and LNCaP cells) induced apoptosis by affecting the methylation status of H3K4 through restraining the expression of KDM5B, which was mentioned elsewhere [41]. *MiR-29a* also largely inhibited the anti-apoptotic ability of OSCC cell via directly targetting matrix metalloproteinase 2 (*MMP2*) gene, thus negatively regulating the expression of MMP2, a well-known oncogenic gene [24]. The apoptosis of GSCs was promoted by *miR-29a* via targetting QKI-6, and the detailed pathway had been mentioned earlier [25]. Similarly, in BCa cells, *miR-29a* showed a great potential in inducing apoptosis partly though targetting TNRF1 [54]. However, Choghaei et al. [56] found that the absence of *miR-29a* promoted apoptosis in breast carcinoma through modulating members of heat shock proteins (HSPs), such as up-regulating HSP60 level and down-regulating HSP27, HSP40, HSP70, and HSP90 levels.

MiR-29a in angiogenesis

Angiogenesis was generally accepted as a consequential characteristic of varied malignant neoplasm, which was a complex process modulated by a sequential pro-angiogenic and anti-angiogenic factors [57]. Generous researches illustrated that *miR-29a* might be relevant with angiogenesis in the development and progression of cancers.

Jia et al. [58] found that *miR-29a* functioned as a suppressor in the expression of vasohibin 2 (VASH2), via the knockdown of H19, one of the long non-coding RNAs (lncRNAs). VASH2 was normally accepted as an angiogenic factor, which could adjust the angiogenesis in glioma. Except VASH2, *miR-29a* apparently repressed the expression and secretion of vascular endothelial growth factor (VEGF), one of the most common proteins liberated from cancer

hsa- <i>miR-29a</i>	Dieases	Target genes	Reference
Down-regulated	PCa	TRIM68	Li et al. [76]
		PGK-1	
		TRAF4	Ahmed et al. [19]
		BMP	
		MCL-1	Pasqualini et al. [77]
	GC	VEGF-A	Chen et al. [78]
		ITGB1	He et al. [80]
		hTERT	
		Robo1	Liu et al. [82]
	HNSCC	LOXL2	Fukumoto et al. [98]
	lung adenocarcinoma	CEACAM6	Han et al. [79]
	NSCLC	LASP1	Hu et al. [50]
		CDC42	Li et al. [51]
	PDAC	TFEB	Kwon et al. [67]
		ATG9A	
	BCa	Robo1	Li et al. [81]
	OSCC	MMP2	Lu et al. [24]
	PTC	PI3K/AKT	Li et al. [83]
	Cholangiocarcinoma	HDAC4	Wang et al. [75]
	Glioma	HSP47	Zhao et al. [84]
Jp-regulated	BCa	TTP	Gebeshuber et al. [71]
		TTP	Al-Ahmadi et al. [73]
		HUR	
		TET1	Pei et al. [52]
	Metastatic hepatoma cell	PTEN	Kong et al. [72]
	CRC	KLF4/MMP2/E-cad	Tang et al. [74]

Table 2 Target genes and dysregulation of miR-29a in metastasis

Abbreviations: BMP, bone morphogenetic protein; CEACAM6, carcinoembryonic antigen-related cell adhesion molecule 6; HNSCC, head and neck squamous cell carcinoma; HSP, heat shock protein; ITGB1, integrin β1; MMP2, matrix metalloproteinase 2; PTC, papillary thyroid carcinoma; PTEN, phosphatase and tensin homolog; Robo1, roundabout 1; TTP, tristetraprolin; VEGF, vascular endothelial growth factor.

Table 2 The role of miD 20a in	the diagnosis d	treatment and sta	and of oproint
Table 3 The role of <i>miR-29a</i> in	the ulayilosis,	treatment, and sta	iges of carcinollia

MiR-29a	Tumors	Proliferation	Apoptosis	Angiogenesis	Drug resistance	Metastasis
Down-regulated	PCa	+	-	-	-	+
	GC	+	-	+	-	+
	PDAC	+	-	-	-	+
	Pancreatic cancer	-	-	-	+	-
	GSCs	+	-	-	-	-
	HCC	+	-	-	-	-
	NSCLC	+	-	-	-	+
	(ALK+)ALCL	-	+	-	-	-
	OSCC	-	+	-	-	+
	Glioma	-	-	+	-	+
	OS	+	-	-	-	-
	HNSCC	-	-	-	-	+
	BCa	-	-	-	-	+
	PTC	-	-	-	-	+
	Cholangiocarcinoma	-	-	-	-	+
	Lung adenocarcinoma	-	-	-	-	+
Up-regulated	BCa	+	+	-	-	+
	Metastatic hepatoma cell	-	-	-	-	+
	CRC	-	-	-	-	+

Abbreviations: ALCL, anaplastic large cell lymphoma; HNSCC, head and neck squamous cell carcinoma; PTC, papillary thyroid carcinoma.



cells that could promote angiogenesis in GC cells [42]. Nevertheless, it was revealed by Wang et al. [59] that miR-29a, modulated by TGF- β in a Smad4-dependent way, served as a promoter in angiogenesis, since miR-29a stimulated the AKT signaling in endothelial cells, by targetting phosphatase and tensin homolog (PTEN). Furthermore, miR-29a, mediated by HMG box-containing protein-1 (HBP1), might regulate the angiogenic properties of human endothelial cells [60]. HBP1, a tumor suppressor protein, was recognized to inhibite Wnt signaling and modulate cell proliferation in BCa cells [61]. As a result, it still remained to explore whether miR-29a functioned as a suppressor or an enhancer in the angiogenesis of tumors.

MiR-29a in drug-resistance

Nowadays, in malignancy, mortality caused by chemotherapy resistance keeps increasing and Sin et al. [62] and Zhang and Yuan [63] speculated that miRNAs might be involved in the therapy of EGFR-tyrosine kinase inhibitors (EGFR-TKIs) resistance in NSCLC. Besides, agilent miRNA microarrays were carried out to examine the miRNA expression profiles of gefitinib-resistant human HCC827/GR-8-1 cell line and the parental HCC827 cell line. Interestingly, *miR-149-5p* was up-regulated in the gefitinib-resistant human HCC827/GR-8-1 cells and associated with acquired gefitinib resistance [64]. Based on the above researches, we learned that miRNAs had showed a great potential in the drug resistance of tumor and a daring hypothesis was made that *miR-29a* took a considerable part in the regulation of chemotherapy resistance.

Cai et al. [65] disclosed previously that miR-29a induced the resistance to gemcitabine (GEM) in pancreatic cancer cells, mediated significantly by the activation the Wnt/ β -catenin signaling pathway. The Wnt/ β -catenin signaling was widely recognized to participate in the chemotherapy resistance of a variety of malignant tumors such as HCC, head and neck tumor, and PCa [66]. Nevertheless, it was confused that Trehoux et al. [47] reported that miR-29a sensitized pancreatic cancer cells to GEM *in vitro* by targetting MUC1. Additionally, Kwon et al. [67] found that miR-29a sensitized chemotherapeutic resistant pancreatic cancer cells to GEM and increased cytotoxicity. Furthermore, miR-29a played an essential role in ADR resistance via inhibiting the PTEN/AKT/GSK3 β pathway in BCa cell lines [68]. Zhong et al. [43] also proved that miR-29a was correlated with drug-resistant ADR and docetaxel (Doc), at least partly by targetting PTEN, which was generally acknowledged as a cancer-depressing gene, and it could also regulate kinds of cell processes, like growth, apoptosis, migration, and invasion [69]. Besides, miR-29a could enhance the chemosensitivity in OSCC, particularly*cis*-Diaminedichloroplatinum (CDDP) [24].

MiR-29a in invasion and metastasis

Metastasis was the most important sequelae in the progression of cancer. Therefore, the mechanism of tumorigenesis and development were urgently needed for the prevention.

It was hypothesized in the 'seed and soil' for metastasis that migratory tumor cells leave the primary tumor via intravasation, disseminating throughout the body by the bloodstream, and eventually implantation in a distant organ. These consecutive steps require close interplay between miRNA and its various targets [70].

Initially, Gebeshuber et al. [71] detected that the up-regulation of miR-29a impaired the expression of tristetraprolin (TTP). TTP was recognized as a protein that was relevant with EMT and negatively modulated AU-rich elements (AREs) containing targets, such as tumor interleukin (IL)-3, IL-8, cyclooxygenase 2 (Cox2), VEGF, c-Myc, cyclin D1, and TNF-a, known as the promotors of tumorigenesis. As a result, the high expression of miR-29a induced invasion and metastasis of tumor in co-operation with oncogenic Ras signaling in human BCa. Moreover, it was also clarified by Kong et al. [72] that miR-29a promoted migration of hepatoma cell mediated by hepatitis B virus X protein (HBx), as it directly inhibited the expression of PTEN and thus regulated Akt phosphorylation. MiR-29a was concerned with the aberrant TTP-HuR axis and promoted the invasiveness of BCa cells [73]. Pei et al. [52] presumed the overexpressed miR-29a facilitated cell growth and migration through down-regulating TET1. And it was discovered by Lu et al. [24] that the enhanced ability to invade and metastasize resulted partly from the excessive expression of miR-29a by directly targetting MMP2 gene in OSCC. Tang et al. [74] also claimed that miR-29a/MMP2 signaling pathway largely contributed to the invasion and metastasis of CRC. They found that miR-29a promoted CRC metastasis through modulating KLF4/MMP2/E-cad. In addition, miR-29a took a great part in the TGF-β1/miR-29a/HDAC4 pathway, which promoted metastasis of cholangiocarcinoma [75]. It was unbelievable that others found miR-29a could also serve as a completely adverse role in the metastasis of tumors. For example Li et al. [76] announced that the up-regulation of miR-29a, mediated by isoflavone inhibited cell growth and invasion. Because of its ability to down-regulate its target genes TRIM68 and PGK-1 in PCa, Ahmed et al. [19] elucidated in 2013 that the up-regulation of miR-29a decreased the expression of the TRAF4. TRAF4 was positively related with the expression of bone morphogenetic proteins (BMPs), which belong to converting growth factor- β (TGF- β) superfamily and are well known to take a



grave part in the bone metastasis of PCa. Accordingly, miR-29a might produce a marked effect on the bone metastasis of PCa through decreasing the expression of BMP, via targetting TRAF4. At the same time, there was also a pathway about c-Myc, Hedgehog, NF-κB/miR-29a/TRAF4 in promoting the invasion and metastasis of PCa, as miR-29a was inhibited by c-Myc, which was overexpressed in PCa. Also, *miR-29a* diminished cell migration partly by directly targetting MCL1 in PCa [77]. MiR-29a functioned as an inhibition role in NSCLC via negatively modulating expression of LASP1 [50] and CDC42 [51], LASP1 functioned as a cAMP- and cGMP-dependent signaling protein and CDC42 was a protein involved in the adjustment of the cell cycle. MiR-29a, directly under-regulating VEGF-A, was identified to inhibit the tumor microvessel density, and then suppressing the invasion and metastasis of GC cells [78]. MiR-29a, accompanied with other tumor-suppressive miRNAs, such as miR-26a/b, miR-29b/c, and miR-218, apparently inhibited the migration and invasion of head and neck squamous cell carcinoma (HNSCC), via directly up-regulating LOXL2 [98]. MiR-29a, through targetting carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6), also inhibited the metastatic behavior of lung adenocarcinoma cells, as CEACAM6 was involved in the adhesion, migration, invasion, and metastasis of tumor cells by integrin receptors [79]. Wound healing and transwell assays conducted by Zhao et al. [46] revealed that miR-29a decreased the metastasis of GC. He et al. [80] further explored that the expression of *miR-29a*, inhibited by the up-regulation of hTERT, enhanced the expression of integrin β 1 (ITGB1) in GC cells, thus leading to the augmented invasive capacity of GC cells. On the other side, restoration of miR-29a restrained the expression of ITGB1 and inhibited GC cell metastasis [80]. MiR-29a reduced the migration and invasion of PDAC cancer cell by the way of blocking autophagy flux, as indicated by an augmentation of autophagosomes and autophagy markers, p62 and LC3B, a reduction in autophagosome-lysosome fusion, as well as the decreased expression of autophagy proteins, TFEB and ATG9A, which are critical for autophagy [67]. The role of miR-29a in inhibiting the metastasis of BCa, at least in part, lied in its negative regulation of Roundabout 1 (Robo1) in MCF-7 BCa cells, through both the expression of Robo1 mRNA and protein [81]. Similarly, Liu et al. [82] acknowledged, in the same year, the same signaling pathway as Li et al. [81] in GC. The up-regulation of miR-29a obviously decreased AKT3 expression, via directly binding to the 3'-UTR of AKT3, thereby suppressing PI3K/AKT pathway activation, which were involved in multiple cellular functions in papillary thyroid carcinoma (PTC) [83]. MiR-29a refrained from glioma tumor growth and invasion through decreasing the expression of HSP47, also known as SER-PINH1. HSP47 was a product of CBP2 gene, located at chromosome 11q13.5, a region frequently amplified in human cancers [84].

MiR-29a in potential clinical application

In clinical application, a desirable biomarker that could facilitate disease detection, stages, and prediction of outcome, and provided appropriate treatment for kinds of cancers. There was emerging evidence for the prognostic role of various miRNAs in cancers. Luckily, the abnormality of *miR-29a* had been found in several types of tumors and might provide novel cancer biomarkers. Exempli gratia, the level of *miR-29a* in serum was significantly correlated with the clinical stage [85]. And the serum levels of *miR-29a* were obviously higher in stage III CRC, compared with levels in the healthy individuals [27]. In stage II CRC, high expression of *miR-29a* was associated with a longer disease-free survival (DFS) [86]. Additionally, higher *miR-29a* levels were significantly related to longer overall survival in metastatic high-grade serous carcinoma [87]. On the other hand, *miR-29a* was also lower in the early-recurrence patients, compared with levels in non-early recurrence group [4], and the same in feces from CRC patients ,compared with those from normality [88]. Meta-analysis of 281 CRC patients and 299 healthy controls [89] revealed that *miR-29a* may be a novel potential biomarker for CRC diagnosis.

Discussion and conclusion

In this review, we focussed on the function of *miR-29a* in the progression of cancers, such as PCa, BCa, lung cancer, GC, PDAC, GSCs, HCC, OSCC, glioma, and so on. Consequently, it regulated a variety of biological processes, including proliferation, apoptosis, angiogenesis, invasion, metastasis, and drug resistance. In opposite, *miR-29a* was discovered to be oncogenically neutral in the pancreatic acinar carcinoma by Dooley et al. [90], no matter the development, nor the growth of pancreatic tumor. In particularly, *miR-29a* exhibited its tissue specificity in BCa, as its up-regulation in the progression of proliferation and metastasis. This phenomenon was quite different from that in other malignant tissue. Commonly, *miR-29a* was down-regulated in kinds of cancers regardless of proliferation, apoptosis, drug resistance, and metastasis. The distinct tissue specificity deserved further researches and might disclose a brand new mechanism in the therapy of malignancy.

In detail, miR-29a was associated with various target genes, like CDK2, MMP2, Wnt/ β -catenin, VEGF, and so on. MMP2, a type IV collagenase, is widely recognized to promote tumor metastasis by decreasing the basement



membrane [91]. CDK2, a member of protein kinase family, significantly modulated abundant events of eukaryotic cell division cycle [92]. VEGF was known to take a great part in the progression and metastasis of cancers through inducing angiogenesis [93]. Thus it can be seen that *miR-29a* adjusted these biological and significant genes and participated in tumorigenesis. However the adjustment of miRNAs is a complex network, which means that an miRNA could regulate multiple target genes, meanwhile, a single gene could be influenced by a variety of miRNAs, including *miR-29a*.

With the development of the depth of the sequencing and the recognition of tumor development, miRNAs were confirmed the relationship with materials which had never caught our eyes, such as extracellular vesicles (EVs), circular RNA, lncRNAs, and autophagy. For example, cell-derived EVs, loaded with functional miRNAs were delivered to the therapeutic targets, which might provide a novel therapies for cancers [94]. In addition, circular RNA modulated the proliferation and invasion of tumors though targetting miRNAs, which provided a novel insight for cancer biology [95-97]. All these potential mechanisms optimized the function of miRNAs. However, no one claimed that *miR-29a* was involved in the above mechanism and whether there were some mysteries about the tumorigenesis and tumor development. We considered that the connection, amongst miRNAs, EVs, circular RNA, lncRNAs, and autophagy, was interesting and urged us for further exploration.

In conclusion, miR-29a participated in cell proliferation, differentiation, apoptosis, angiogenesis, tumorigenicity, metastasis, drug-resistance, and so on. Increasing researches were involved in the function of miR-29a and the new findings or mechanism might also be related with miR-29a. We suggested that miR-29a serve as a potential therapeutic target and promising biomarker in various tumors, in future miR-29a requires further exploration.

Author contribution

S.-I.Z., D.-d.W. and H.-h.S. were responsible for the useful discussions and helped in revision of the present paper. All authors were responsible for the content and writing of the paper.

Competing interests

The authors declare that there are no competing interests associated with the manuscript.

Funding

This work was supported by the National Natural Science Foundation of China [grant number 81602551]; the Key Research Program for the Social Development of Jiangsu Province, China [grant number BE2015718]; the National Program on Key Research Project [grant number 2016YFC0905900]; the Medical Training Programme Foundation for the Talents by Jiangsu Provincial Department of Health [grant number 17 [2016]]; the 333 Talent Project of Jiangsu Province, top-level [grant number 4 [2016]]; the National Key Clinical Specialist Construction Programs of China [grant number 544 [2013]]; the Major Program of Natural Science Foundation of Jiangsu Province [grant number BL2014090]; the Natural Science Foundation of Jiangsu Province [grant number BK20151579]; a project funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD) [grant number JX10231802]; and the Postgraduate Research and Practice Innovation Program of Jiangsu Province [grant number SJCX17_0387].

Abbreviations

BCa, breast cancer; BMP, bone morphogenetic protein; CDC42, cell division control protein 42 homolog; CDK, cyclin-dependent kinase; CEACAM6, carcinoembryonic antigen-related cell adhesion molecule 6; CRC, colorectal cancer; EGFR, epidermal growth factor receptor; EMT, epithelial-to-mesenchymal transition; EV, extracellular vesicle; GC, gastric cancer; GEM, gemcitabine; GSC, glioblastoma stem cell; HBP1, HMG box-containing protein-1; HCC, hepatocellular carcinoma; HSP, heat shock protein; ITGB1, integrin β1; LASP1, LIM and SH3 domain protein 1; IncRNA, long non-coding RNA; MCL-1, myeloid cell leukemia 1; MUC1, mucin 1; MMP2, matrix metalloproteinase 2; NSCLC, non-small-cell lung cancer; OSCC, oral squamous carcinoma; PCa, prostate cancer; PDAC, pancreatic ductal adenocarcinoma; PI3K, phosphoinositide 3-kinase; PTEN, phosphatase and tensin homolog; QKI-6, quaking gene isoform 6; Robo1, roundabout 1; TET1, ten eleven translocation 1; TNF, tumor necrosis factor; TNFR, TNF receptor; TTP, tristetraprolin; VASH2, vasohibin 2; VEGF, vascular endothelial growth factor.

References

- 1 Siegel, R.L., Miller, K.D. and Jemal, A. (2017) Cancer statistics, 2017. CA Cancer J. Clin. 67, 7–30, https://doi.org/10.3322/caac.21387
- 2 Wang, D.D. et al. (2016) miR-197: a novel biomarker for cancers. Gene 591, 313-319, https://doi.org/10.1016/j.gene.2016.06.035
- 3 Zhang, H.D. et al. (2015) MiR-139-5p: promising biomarker for cancer. Tumour Biol. 36, 1355–1365, https://doi.org/10.1007/s13277-015-3199-3



- 4 Kuo, T.Y. et al. (2012) Computational analysis of mRNA expression profiles identifies microRNA-29a/c as predictor of colorectal cancer early recurrence. *PLoS ONE* **7**, e31587, https://doi.org/10.1371/journal.pone.0031587
- 5 Zhang, H.D. et al. (2015) MiR-139-5p inhibits the biological function of breast cancer cells by targeting Notch1 and mediates chemosensitivity to docetaxel. *Biochem. Biophys. Res. Commun.* **465**, 702–713, https://doi.org/10.1016/j.bbrc.2015.08.053
- 6 Cho, W.C. (2010) MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. *Int. J. Biochem. Cell Biol.* **42**, 1273–1281, https://doi.org/10.1016/j.biocel.2009.12.014
- 7 Liu, X. et al. (2016) MicroRNA as regulators of cancer stem cells and chemoresistance in colorectal cancer. *Curr. Cancer Drug Targets* **16**, 738–754, https://doi.org/10.2174/1568009616666151118114759
- 8 Li, H.C. et al. (2017) Loss of the Opa interacting protein 5 inhibits breast cancer proliferation through miR-139-5p/NOTCH1 pathway. Gene 603, 1–8, https://doi.org/10.1016/j.gene.2016.11.046
- 9 Zhang, J.K. et al. (2017) Up-regulation of CRKL by microRNA-335 methylation is associated with poor prognosis in gastric cancer. *Cancer Cell Int.* **17**, 28, https://doi.org/10.1186/s12935-017-0387-9
- 10 Shen, H. et al. (2017) MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/F0X01 pathway. *Gene* **596**, 110–118, https://doi.org/10.1016/j.gene.2016.10.016
- 11 Qiu, K. et al. (2016) miR-22 regulates cell invasion, migration and proliferation *in vitro* through inhibiting CD147 expression in tongue squamous cell carcinoma. *Arch. Oral. Biol.* **66**, 92–97, https://doi.org/10.1016/j.archoralbio.2016.02.013
- 12 Qi, Y. et al. (2017) Prognostic value of the microRNA-29 family in multiple human cancers: a meta-analysis and systematic review. *Clin. Exp. Pharmacol. Physiol.* **44**, 441–454
- 13 Plaisier, C.L., Pan, M. and Baliga, N.S. (2012) A miRNA-regulatory network explains how dysregulated miRNAs perturb oncogenic processes across diverse cancers. *Genome Res.* 22, 2302–2314, https://doi.org/10.1101/gr.133991.111
- 14 Zhang, H. et al. (2015) MicroRNA-29s could target AKT2 to inhibit gastric cancer cells invasion ability. *Med. Oncol.* **32**, 342, https://doi.org/10.1007/s12032-014-0342-8
- 15 Kato, M. et al. (2017) Regulation of metastasis-promoting LOXL2 gene expression by antitumor microRNAs in prostate cancer. *J. Hum. Genet.* **62**, 123–132, https://doi.org/10.1038/jhg.2016.68
- 16 Parafioriti, A. et al. (2016) Ewing's sarcoma: an analysis of miRNA expression profiles and target genes in paraffin-embedded primary tumor tissue. *Int. J. Mol. Sci.* **17**, https://doi.org/10.3390/ijms17050656
- 17 Ma, J. et al. (2017) MicroRNA-29a inhibits proliferation and motility of Schwannoma cells by targeting CDK6. J. Cell. Biochem., https://doi.org/10.1002/jcb.26426
- 18 Yan, B. et al. (2015) The role of miR-29b in cancer: regulation, function, and signaling. Onco Targets Ther. 8, 539–548
- 19 Ahmed, F. et al. (2013) Tumor necrosis factor receptor associated factor-4: an adapter protein overexpressed in metastatic prostate cancer is regulated by microRNA-29a. *Oncol. Rep.* **30**, 2963–2968, https://doi.org/10.3892/or.2013.2789
- 20 Xu, L. et al. (2014) Altered expression pattern of miR-29a, miR-29b and the target genes in myeloid leukemia. *Exp. Hematol. Oncol.* **3**, 17, https://doi.org/10.1186/2162-3619-3-17
- 21 Muluhngwi, P. et al. (2017) Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells. *Cancer Lett.* **388**, 230–238, https://doi.org/10.1016/j.canlet.2016.12.007
- 22 Barkley, L.R. and Santocanale, C. (2013) MicroRNA-29a regulates the benzo[a]pyrene dihydrodiol epoxide-induced DNA damage response through Cdc7 kinase in lung cancer cells. *Oncogenesis* **2**, e57, https://doi.org/10.1038/oncsis.2013.20
- 23 Desjobert, C. et al. (2011) MiR-29a down-regulation in ALK-positive anaplastic large cell lymphomas contributes to apoptosis blockade through MCL-1 overexpression. *Blood* **117**, 6627–6637, https://doi.org/10.1182/blood-2010-09-301994
- 24 Lu, L. et al. (2014) MicroRNA-29a upregulates MMP2 in oral squamous cell carcinoma to promote cancer invasion and anti-apoptosis. *Biomed. Pharmacother.* **68**, 13–19, https://doi.org/10.1016/j.biopha.2013.10.005
- 25 Xi, Z. et al. (2017) Overexpression of miR-29a reduces the oncogenic properties of glioblastoma stem cells by downregulating Quaking gene isoform 6. Oncotarget
- 26 Deng, Y. and Chen, Y. (2017) Increased expression of miR-29a and its prognostic significance in patients with cholangiocarcinoma. *Oncol. Res. Treat.*, https://doi.org/10.1159/000455869
- 27 Brunet Vega, A. et al. (2013) microRNA expression profile in stage III colorectal cancer: circulating miR-18a and miR-29a as promising biomarkers. *Oncol. Rep.* **30**, 320–326, https://doi.org/10.3892/or.2013.2475
- 28 Wei, J. et al. (2015) MicroRNAs as regulators of airborne pollution-induced lung inflammation and carcinogenesis. Arch. Toxicol. 89, 677–685, https://doi.org/10.1007/s00204-015-1462-4
- 29 Muller, M. et al. (2016) MicroRNA-29a is a candidate biomarker for Alzheimer's disease in cell-free cerebrospinal fluid. *Mol. Neurobiol.* 53, 2894–2899, https://doi.org/10.1007/s12035-015-9156-8
- 30 Goldschmidt, I., Thum, T. and Baumann, U. (2016) Circulating miR-21 and miR-29a as markers of disease severity and etiology in cholestatic pediatric liver disease. J. Clin. Med. 5, https://doi.org/10.3390/jcm5030028
- 31 Huang, Y.Q. et al. (2016) The relationship of plasma miR-29a and oxidized low density lipoprotein with atherosclerosis. *Cell. Physiol. Biochem.* **40**, 1521–1528, https://doi.org/10.1159/000453202
- 32 Zhao, Y., Yuan, Y. and Qiu, C. (2016) Underexpression of CACNA1C caused by overexpression of microRNA-29a underlies the pathogenesis of atrial fibrillation. *Med. Sci. Monit.* 22, 2175–2181, https://doi.org/10.12659/MSM.896191
- 33 Afum-Adjei Awuah, A. et al. (2014) Dynamics of T-cell IFN-gamma and miR-29a expression during active pulmonary tuberculosis. Int. Immunol. 26, 579–582, https://doi.org/10.1093/intimm/dxu068



- 34 Jones, J.A. et al. (2011) Selective microRNA suppression in human thoracic aneurysms: relationship of miR-29a to aortic size and proteolytic induction. *Circ. Cardiovasc. Genet.* **4**, 605–613, https://doi.org/10.1161/CIRCGENETICS.111.960419
- 35 Millar, N.L. et al. (2015) MicroRNA29a regulates IL-33-mediated tissue remodelling in tendon disease. *Nat. Commun.* **6**, 6774, https://doi.org/10.1038/ncomms7774
- 36 Yang, Y.L. et al. (2017) MicroRNA-29a alleviates bile duct ligation exacerbation of hepatic fibrosis in mice through epigenetic control of methyltransferases. Int. J. Mol. Sci. 18
- 37 Huang, J. et al. (2013) Elevated miR-29a expression is not correlated with disease activity index in PBMCs of patients with ankylosing spondylitis. *Mod. Rheumatol.*, https://doi.org/10.1007/s10165-013-0891-2
- 38 Hsu, Y.C. et al. (2016) Protective effects of miR-29a on diabetic glomerular dysfunction by modulation of DKK1/Wnt/beta-catenin signaling. *Sci. Rep.* 6, 30575, https://doi.org/10.1038/srep30575
- 39 Kawashita, Y. et al. (2011) Circulating miR-29a levels in patients with scleroderma spectrum disorder. J. Dermatol. Sci. 61, 67–69, https://doi.org/10.1016/j.jdermsci.2010.11.007
- 40 Mattis, A.N. et al. (2015) A screen in mice uncovers repression of lipoprotein lipase by microRNA-29a as a mechanism for lipid distribution away from the liver. *Hepatology* **61**, 141–152, https://doi.org/10.1002/hep.27379
- 41 Li, J. et al. (2015) MiR-29a suppresses prostate cell proliferation and induces apoptosis via KDM5B protein regulation. Int. J. Clin. Exp. Med. 8, 5329–5339
- 42 Zhang, H. et al. (2016) Cell-derived microvesicles mediate the delivery of miR-29a/c to suppress angiogenesis in gastric carcinoma. *Cancer Lett.* **375**, 331–339, https://doi.org/10.1016/j.canlet.2016.03.026
- 43 Zhong, S. et al. (2013) MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells. *Gene* **531**, 8–14, https://doi.org/10.1016/j.gene.2013.08.062
- 44 Zhu, D.Q. et al. (2014) Nucleotidyl transferase TUT1 inhibits lipogenesis in osteosarcoma cells through regulation of microRNA-24 and microRNA-29a. *Turnour Biol.* **35**, 11829–11835, https://doi.org/10.1007/s13277-014-2395-x
- 45 Cui, Y. et al. (2011) MiR-29a inhibits cell proliferation and induces cell cycle arrest through the downregulation of p42.3 in human gastric cancer. *PLoS ONE* **6**, e25872, https://doi.org/10.1371/journal.pone.0025872
- 46 Zhao, Z. et al. (2015) Reduced miR-29a-3p expression is linked to the cell proliferation and cell migration in gastric cancer. *World J. Surg. Oncol.* **13**, 101, https://doi.org/10.1186/s12957-015-0513-x
- 47 Trehoux, S. et al. (2015) Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by targeting the MUC1 mucin in pancreatic cancer cells. *Biochim. Biophys. Acta* **1853**, 2392–2403, https://doi.org/10.1016/j.bbamcr.2015.05.033
- 48 Trehoux, S. et al. (2015) The MUC1 oncomucin regulates pancreatic cancer cell biological properties and chemoresistance. Implication of p42-44 MAPK, Akt, Bcl-2 and MMP13 pathways. *Biochem. Biophys. Res. Commun.* **456**, 757–762, https://doi.org/10.1016/j.bbrc.2014.12.025
- 49 Zhu, X.C. et al. (2012) microRNA-29a suppresses cell proliferation by targeting SPARC in hepatocellular carcinoma. *Int. J. Mol. Med.* **30**, 1321–1326, https://doi.org/10.3892/ijmm.2012.1140
- 50 Hu, Z. et al. (2016) MicroRNA-29a plays a suppressive role in non-small cell lung cancer cells via targeting LASP1. Onco Targets Ther. 9, 6999–7009, https://doi.org/10.2147/0TT.S116509
- 51 Li, Y. et al. (2017) MicroRNA-29a functions as a potential tumor suppressor through directly targeting CDC42 in non-small cell lung cancer. *Oncol. Lett.* **13**, 3896–3904
- 52 Pei, Y.F., Lei, Y. and Liu, X.Q. (2016) MiR-29a promotes cell proliferation and EMT in breast cancer by targeting ten eleven translocation 1. *Biochim. Biophys. Acta* **1862**, 2177–2185, https://doi.org/10.1016/j.bbadis.2016.08.014
- 53 Kudo, Y. et al. (2011) Loss of 5-hydroxymethylcytosine is accompanied with malignant cellular transformation. *Cancer Sci.*, https://doi.org/10.1111/j.1349-7006.2012.02213.x
- 54 Zhao, Y. et al. (2017) miR-29a suppresses MCF-7 cell growth by downregulating tumor necrosis factor receptor 1. *Tumour Biol.* **39**, 1010428317692264, https://doi.org/10.1177/1010428317692264
- 55 Green, D. (2011) Means to an End: Apoptosis and other Cell Death Mechanisms, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
- 56 Choghaei, E. et al. (2016) Knockdown of microRNA-29a changes the expression of heat shock proteins in breast carcinoma MCF-7 cells. *Oncol. Res.* **23**, 69–78, https://doi.org/10.3727/096504015X14478843952906
- 57 Yuan, B., Xian, R., Ma, J., Chen, Y., Lin, C. and Song, Y. (2012) Isthmin inhibits glioma growth through antiangiogenesis *in vivo. J. Neurooncol.* **109**, 245–252, https://doi.org/10.1007/s11060-012-0910-8
- 58 Jia, P. et al. (2016) Long non-coding RNA H19 regulates glioma angiogenesis and the biological behavior of glioma-associated endothelial cells by inhibiting microRNA-29a. *Cancer Lett.* **381**, 359–369, https://doi.org/10.1016/j.canlet.2016.08.009
- 59 Wang, J. et al. (2013) Transforming growth factor beta-regulated microRNA-29a promotes angiogenesis through targeting the phosphatase and tensin homolog in endothelium. *J. Biol. Chem.* **288**, 10418–10426, https://doi.org/10.1074/jbc.M112.444463
- 60 Yang, Z. et al. (2013) MiR-29a modulates the angiogenic properties of human endothelial cells. *Biochem. Biophys. Res. Commun.* **434**, 143–149, https://doi.org/10.1016/j.bbrc.2013.03.054
- 61 Paulson, K.E. et al. (2007) Alterations of the HBP1 transcriptional repressor are associated with invasive breast cancer. *Cancer Res.* 67, 6136–6145, https://doi.org/10.1158/0008-5472.CAN-07-0567
- 62 Sin, T.K. et al. (2016) Implications of MicroRNAs in the treatment of gefitinib-resistant non-small cell lung cancer. Int. J. Mol. Sci. 17, 237, https://doi.org/10.3390/ijms17020237
- 63 Zhang, K. and Yuan, Q. (2016) Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer. *J. Can. Res. Ther.* **12**, C131–C137, https://doi.org/10.4103/0973-1482.200613



- 64 Hu, Y. et al. (2017) Genome-wide profiling of micro-RNA expression in gefitinib-resistant human lung adenocarcinoma using microarray for the identification of miR-149-5p modulation. *Tumour Biol.* **39**, 1010428317691659, https://doi.org/10.1177/1010428317691659
- 65 Cai, A.P. et al. (2013) MicroRNA-29a induces resistance to gemcitabine through the Wnt/beta-catenin signaling pathway in pancreatic cancer cells. *Int. J. Oncol.* **43**, 1066–1072, https://doi.org/10.3892/ijo.2013.2037
- 66 Noda, T., Nagano, H., Takemasa, I., Yoshioka, S., Murakami, M., Wada, H. et al. (2009) Activation of Wnt/b-catenin signalling pathway induces chemoresistance to interferon-a/5-fluorouracil combination therapy for hepatocellular carcinoma. *Br. J. Cancer*, https://doi.org/10.1038/sj.bjc.6605064
- 67 Kwon, J.J. et al. (2016) Novel role of miR-29a in pancreatic cancer autophagy and its therapeutic potential. *Oncotarget* **7**, 71635–71650
- 68 Shen, H. et al. (2016) MicroRNA-29a contributes to drug-resistance of breast cancer cells to adriamycin through PTEN/AKT/GSK3beta signaling pathway. *Gene* **593**, 84–90, <u>https://doi.org/10.1016/j.gene.2016.08.016</u>
- 69 Yamada, , K.M. and Araki, M. (2001) Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. *J. Cell Sci.* **114**, 2375–2382
- 70 Paget, S. (1989) The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 8, 98–101
- 71 Gebeshuber, C.A., Zatloukal, K. and Martinez, J. (2009) miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. *EMBO Rep.* **10**, 400–405, https://doi.org/10.1038/embor.2009.9
- 72 Kong, G. et al. (2011) Upregulated microRNA-29a by hepatitis B virus X protein enhances hepatoma cell migration by targeting PTEN in cell culture model. *PLoS ONE* **6**, e19518, https://doi.org/10.1371/journal.pone.0019518
- 73 AI-Ahmadi, W. et al. (2013) miR-29a inhibition normalizes HuR over-expression and aberrant AU-rich mRNA stability in invasive cancer. J. Pathol. 230, 28–38, https://doi.org/10.1002/path.4178
- 74 Tang, W. et al. (2014) MicroRNA-29a promotes colorectal cancer metastasis by regulating matrix metalloproteinase 2 and E-cadherin via KLF4. Br. J. Cancer **110**, 450–458, https://doi.org/10.1038/bjc.2013.724
- 75 Wang, H. et al. (2015) TGF-beta1 reduces miR-29a expression to promote tumorigenicity and metastasis of cholangiocarcinoma by targeting HDAC4. *PLoS ONE* **10**, e0136703, https://doi.org/10.1371/journal.pone.0136703
- 76 Li, Y. et al. (2012) Epigenetic deregulation of miR-29a and miR-1256 by isoflavone contributes to the inhibition of prostate cancer cell growth and invasion. *Epigenetics* **7**, 940–949, https://doi.org/10.4161/epi.21236
- 77 Pasqualini, L. et al. (2015) miR-22 and miR-29a are members of the androgen receptor cistrome modulating LAMC1 and McI-1 in prostate cancer. *Mol. Endocrinol.* 29, 1037–1054, https://doi.org/10.1210/me.2014-1358
- 78 Chen, L. et al. (2014) miR-29a suppresses growth and invasion of gastric cancer cells in vitro by targeting VEGF-A. BMB Rep. 47, 39–44, https://doi.org/10.5483/BMBRep.2014.47.1.079
- 79 Han, H.S. et al. (2014) MicroRNA-29a suppresses the growth, migration, and invasion of lung adenocarcinoma cells by targeting carcinoembryonic antigen-related cell adhesion molecule 6. *FEBS Lett.* **588**, 3744–3750, https://doi.org/10.1016/j.febslet.2014.08.023
- 80 He, B. et al. (2016) hTERT mediates gastric cancer metastasis partially through the indirect targeting of ITGB1 by microRNA-29a. *Sci. Rep.* 6, 21955, https://doi.org/10.1038/srep21955
- 81 Li, H. et al. (2015) MicroRNA-29a inhibits cell migration and invasion by targeting Roundabout 1 in breast cancer cells. *Mol. Med. Rep.* **12**, 3121–3126, https://doi.org/10.3892/mmr.2015.3749
- 82 Liu, X. et al. (2015) MicroRNA-29a inhibits cell migration and invasion via targeting Roundabout homolog 1 in gastric cancer cells. *Mol. Med. Rep.* **12**, 3944–3950, https://doi.org/10.3892/mmr.2015.3817
- 83 Li, R. et al. (2016) miR-29a suppresses growth and metastasis in papillary thyroid carcinoma by targeting AKT3. *Tumour Biol.* **37**, 3987–3996, https://doi.org/10.1007/s13277-015-4165-9
- 84 Zhao, D. et al. (2014) Heat shock protein 47 regulated by miR-29a to enhance glioma tumor growth and invasion. J. Neurooncol. **118**, 39–47, https://doi.org/10.1007/s11060-014-1412-7
- 85 Faltejskova, P. et al. (2012) Circulating miR-17-3p, miR-29a, miR-92a and miR-135b in serum: Evidence against their usage as biomarkers in colorectal cancer. *Cancer Biomark*. **12**, 199–204, https://doi.org/10.3233/CBM-130308
- 86 Weissmann-Brenner, A. et al. (2012) Tumor microRNA-29a expression and the risk of recurrence in stage II colon cancer. Int. J. Oncol. 40, 2097–2103
- 87 Nymoen, D.A. et al. (2016) MiR-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma. *Hum. Pathol.* **54**, 74–81, https://doi.org/10.1016/j.humpath.2016.03.010
- 88 Zhu, Y. et al. (2016) Fecal miR-29a and miR-224 as the noninvasive biomarkers for colorectal cancer. Cancer Biomark. 16, 259–264, https://doi.org/10.3233/CBM-150563
- 89 Zhi, M.L. et al. (2015) Diagnostic performance of microRNA-29a for colorectal cancer: a meta-analysis. *Genet. Mol. Res.* 14, 18018–18025, https://doi.org/10.4238/2015.December.22.28
- 90 Dooley, J. et al. (2017) miR-29a-deficiency does not modify the course of murine pancreatic acinar carcinoma. Oncotarget 8, 26911–26917
- 91 Li, S. et al. (2017) Restoration of KLF4 inhibits invasion and metastases of lung adenocarcinoma through suppressing MMP2. J. Cancer 8, 3480–3489, https://doi.org/10.7150/jca.21241
- 92 Chohan, T.A. et al. (2015) Cyclin-dependent kinase-2 as a target for cancer therapy: progress in the development of CDK2 inhibitors as anti-cancer agents. *Curr. Med. Chem.* **22**, 237–263, https://doi.org/10.2174/0929867321666141106113633
- 93 Lim, J. et al. (2015) Inhibition of vascular endothelial growth factor receptor 3 reduces migration of gastric cancer cells. *Cancer Invest.* **33**, 398–404, https://doi.org/10.3109/07357907.2015.1047509
- 94 Wang, F. et al. (2017) Exosome miR-335 as a novel therapeutic strategy in hepatocellular carcinoma. Hepatology, https://doi.org/10.1002/hep.29586
- 95 Zhang, J. et al. (2017) Circular RNA_LARP4 inhibits cell proliferation and invasion of gastric cancer by sponging miR-424-5p and regulating LATS1 expression. *Mol. Cancer* **16**, 151, https://doi.org/10.1186/s12943-017-0719-3



- 96 Tang, Y.Y. et al. (2017) Circular RNA hsa_circ_0001982 promotes breast cancer cell carcinogenesis through decreasing miR-143. DNA Cell Biol. 36, 901–908, https://doi.org/10.1089/dna.2017.3862
- 97 Liang, H.F. et al. (2017) Circular RNA circ-ABCB10 promotes breast cancer proliferation and progression through sponging miR-1271. Am. J. Cancer Res. 7, 1566–1576
- 98 Fukumoto, I. (2016) Tumor-suppressive microRNAs (miR-26a/b, miR-29a/b/c and miR-218) concertedly suppressed metastasis-promoting LOXL2 in head and neck squamous cell carcinoma.. *J Hum Genet* **61**, 109–118, https://doi.org/10.1038/jhg.2015.120